Enthera's Approach To Type 1 Diabetes Attracts Corporate VCs
Large Series A For Italian Biotech
Italy’s four-year-old Enthera Pharmaceuticals is developing antibodies targeted at restoring pancreatic beta cells in type 1 diabetes, and has attracted corporate investors to its series A funding.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.